Cyclocarya paliurus Leaf Polyphenols Research Advances and Evidence Gaps 2024 to 2026
Share
Key conclusion
2024至2026年的研究进一步揭示了青钱柳叶中多酚、黄酮、皂苷等成分与代谢调节、肠道微生态、氧化反应和食品风味之间的潜在联系。但目前证据仍以化学分析、细胞实验和动物研究为主。本次检索未识别到以符合2026年中国获批规格的标准化青钱柳叶多酚为干预物、经过同行评审发表的人体随机对照试验。因此，青钱柳叶多酚具有继续开发的科学基础，但不应被描述为已经证实能够在人体中降血糖、降血脂、减肥或治疗疾病。
Research published from 2024 to 2026 has added useful information on the relationships between polyphenols, flavonoids, saponins and other constituents in Cyclocarya paliurus leaves and metabolic regulation, the gut ecosystem, oxidative reactions and food sensory properties. Most evidence, however, still comes from chemical analysis, cell experiments and animal models. Our search did not identify a peer-reviewed randomized human trial using a standardized Cyclocarya paliurus leaf polyphenol ingredient matching the Chinese specification approved in 2026. The ingredient therefore has a credible scientific basis for further development, but it should not be presented as clinically proven to lower blood glucose or lipids, reduce body weight, or treat disease.
The research materials are not interchangeable
“青钱柳研究”并不等于“青钱柳叶多酚成品研究”。现有论文使用的材料包括整片叶、青钱柳茶、热水或醇提取物、黄酮组分、多糖组分、总多酚组分以及单体化合物。不同材料的化学组成、剂量和吸收特征可能明显不同。只有当研究对象、提取工艺和质量规格相近时，研究结果才可能对商业原料产生较强的直接参考价值。
Research on Cyclocarya paliurus is not automatically research on a finished Cyclocarya paliurus leaf polyphenol ingredient. Published studies have used whole leaves, herbal tea, aqueous or ethanolic extracts, flavonoid fractions, polysaccharide fractions, total-polyphenol fractions and isolated compounds. These materials may differ substantially in composition, dose and absorption. A study becomes directly relevant to a commercial ingredient only when the test material, extraction process and quality specification are sufficiently comparable.
这一差异对B2B采购尤其重要。一个标注为10比1的普通青钱柳叶提取物，不一定符合中国2026年青钱柳叶多酚的总多酚、总皂苷和总黄酮要求；同样，动物实验中的青钱柳叶粉也不能自动代表标准化多酚粉末的效果。
This distinction is particularly important in B2B sourcing. A generic 10:1 Cyclocarya paliurus leaf extract does not necessarily meet the Chinese 2026 requirements for total polyphenols, total saponins and total flavonoids. Likewise, results obtained with whole leaf powder in animals cannot automatically be attributed to a standardized polyphenol powder.
Animal research suggests gut and metabolic pathways
2024年发表于Aging的研究使用高蔗糖膳食小鼠，观察到青钱柳叶干预与体重、脂肪沉积、空腹血糖、胰岛素抵抗指标和血脂指标的变化相关。研究还分析了肠道菌群和代谢物，并使用粪菌移植探讨菌群是否参与相关效应。结果为“青钱柳可能通过肠道菌群和微生物代谢物影响代谢状态”提供了临床前线索。
A 2024 study in Aging used mice fed a high-sucrose diet and reported associations between Cyclocarya paliurus leaf intervention and changes in body weight, fat deposition, fasting glucose, insulin-resistance indices and serum lipids. The researchers also examined gut microbiota and metabolites and used fecal microbiota transplantation to investigate whether the microbial community contributed to the observed effects. The work provides preclinical support for a possible gut-microbiota and microbial-metabolite pathway.
这项研究的价值在于机制探索，而不是人体功效确认。实验对象是小鼠，样本规模有限，干预材料也不是按照2026年中国新食品原料规格生产的商业化青钱柳叶多酚。文章中可以讨论这些科学信号，但不能把它们翻译成消费者层面的确定功效。
Its value lies in mechanism exploration rather than confirmation of human efficacy. The subjects were mice, the sample size was limited, and the test material was not a commercial Cyclocarya paliurus leaf polyphenol ingredient manufactured to the Chinese 2026 specification. The scientific signals are worth discussing, but they should not be translated into definitive consumer benefits.
Cell and mechanistic studies generate hypotheses
2024年Journal of Functional Foods发表的研究围绕青钱柳叶黄酮和PIK3CA相关通路展开，探索黄酮组分与胰岛细胞功能及胰岛素分泌机制之间的关系。此类研究可以帮助科研人员锁定潜在靶点，也可以指导后续成分鉴定和动物验证。
A 2024 paper in the Journal of Functional Foods investigated a Cyclocarya paliurus leaf flavonoid fraction in relation to PIK3CA-associated signaling, pancreatic beta-cell function and insulin-secretion mechanisms. Such work can help researchers identify possible molecular targets and guide subsequent compound identification and animal validation.
但细胞模型无法模拟真实人体中的消化、吸收、代谢、剂量和长期安全性。即使某种黄酮在细胞水平显示活性，也不能证明含有该黄酮的复合植物原料在人体中具有相同效果。
A cell model cannot reproduce human digestion, absorption, metabolism, effective dose or long-term safety. Activity observed for a flavonoid fraction at the cellular level does not demonstrate that a complex botanical ingredient containing that flavonoid will produce the same effect in people.
Harvest month is becoming a quality variable
2024年的多平台代谢组学研究显示，青钱柳叶中的酚类、黄酮、多糖、皂苷及甜味和苦味相关物质会随生长期变化。2025年的转录组与代谢组联合研究进一步观察到黄酮积累具有明显季节性，并识别了与黄酮合成相关的基因和调控因子。2026年的一项单产地先导研究也发现，不同月份叶片水提物的总酚、总黄酮、挥发性成分以及体外自由基清除和抗糖化指标存在差异。
A 2024 multiplatform metabolomics study found that phenolics, flavonoids, polysaccharides, saponins and compounds associated with sweetness and bitterness varied across the growing season. A 2025 combined transcriptomic and metabolomic study further showed marked seasonal patterns in flavonoid accumulation and identified genes and regulators associated with flavonoid biosynthesis. A one-site pilot study published in 2026 also reported month-related differences in total phenolics, flavonoids, volatile compounds, radical-scavenging assays and an in vitro antiglycation model.
这些结果对产业化的直接意义不是寻找一个适用于所有地区的“最佳月份”，而是把产区、气候、采收月份、叶片成熟度和储存条件纳入原料控制。供应商需要通过本地数据确定自己的采收窗口，而不能简单复制另一产区的研究结论。
The industrial implication is not that one month is universally optimal. Region, climate, harvest month, leaf maturity and storage conditions should be treated as raw-material control variables. Each supplier needs local evidence to define its own harvest window instead of copying the conclusion of a study
What research is needed next
下一步最有价值的工作包括：明确研究样品的植物来源和提取工艺；公布总多酚、总黄酮、总皂苷及特征成分；建立HPLC指纹；开展消化稳定性和生物利用度研究；完成规范的毒理学与相互作用评价；最终使用标准化原料开展设计充分、预注册的人体研究。
The most valuable next steps include clear botanical and process characterization of test materials; disclosure of total polyphenols, flavonoids, saponins and characteristic compounds; an HPLC fingerprint; digestive-stability and bioavailability research; appropriate toxicology and interaction assessment; and ultimately well-designed, preregistered human studies using a standardized ingredient.
对原料企业而言，科研传播应与质量证据同步。湖北晟美康已经取得明确包含青钱柳叶多酚的食品生产许可并已正式投产，具备相应的生产和质量检验能力。具体产品规格及批次数据以正式COA为准。
For ingredient manufacturers, scientific communication should progress together with quality evidence. Hubei Shengmei Kang has obtained a food production license that explicitly includes Cyclocarya paliurus leaf polyphenols and has commenced commercial production, supported by corresponding manufacturing and quality-testing capabilities. Product specifications and batch-specific data are subject to the official certificate of analysis.
参考资料 References
Yao et al. Cyclocarya paliurus leaves alleviate high-sucrose diet-induced obesity. Aging 2024. https://www.aging-us.com/article/205657/text
Wang et al. Antidiabetic effects and mechanisms of Cyclocarya paliurus leaf flavonoids via PIK3CA. Journal of Functional Foods 2024. https://doi.org/10.1016/j.jff.2024.106031
Chen et al. Metabolite profiling and identification of sweet and bitter taste compounds. Foods 2024. https://www.mdpi.com/2304-8158/13/19/3089
Chen et al. Seasonal dynamics and molecular regulation of flavonoid biosynthesis. Frontiers in Plant Science 2025. https://doi.org/10.3389/fpls.2025.1525226
Fu et al. Growth month-associated variation in volatile profiles and in vitro activities. Foods 2026. https://www.mdpi.com/2304-8158/15/12/2183